KR102188437B1 - Rsv 특이적 항체 및 이의 기능적 부위 - Google Patents

Rsv 특이적 항체 및 이의 기능적 부위 Download PDF

Info

Publication number
KR102188437B1
KR102188437B1 KR1020167020393A KR20167020393A KR102188437B1 KR 102188437 B1 KR102188437 B1 KR 102188437B1 KR 1020167020393 A KR1020167020393 A KR 1020167020393A KR 20167020393 A KR20167020393 A KR 20167020393A KR 102188437 B1 KR102188437 B1 KR 102188437B1
Authority
KR
South Korea
Prior art keywords
seq
delete delete
antibody
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167020393A
Other languages
English (en)
Korean (ko)
Other versions
KR20160104018A (ko
Inventor
낸시 울브란트
니콜 캘리워드-릴레이
앤디 큐 위안
베티나 리히터
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20160104018A publication Critical patent/KR20160104018A/ko
Application granted granted Critical
Publication of KR102188437B1 publication Critical patent/KR102188437B1/ko
Assigned to 메디뮨 리미티드 reassignment 메디뮨 리미티드 권리의 전부이전등록 Assignors: 메디뮨 엘엘씨
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167020393A 2014-01-15 2015-01-14 Rsv 특이적 항체 및 이의 기능적 부위 Active KR102188437B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
US61/927,819 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Publications (2)

Publication Number Publication Date
KR20160104018A KR20160104018A (ko) 2016-09-02
KR102188437B1 true KR102188437B1 (ko) 2020-12-08

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167020393A Active KR102188437B1 (ko) 2014-01-15 2015-01-14 Rsv 특이적 항체 및 이의 기능적 부위

Country Status (26)

Country Link
US (6) US20160340414A1 (https=)
EP (3) EP3741390A1 (https=)
JP (4) JP6836398B2 (https=)
KR (1) KR102188437B1 (https=)
CN (2) CN116355080A (https=)
AU (4) AU2015206570A1 (https=)
CA (1) CA2933200C (https=)
CY (2) CY1123425T1 (https=)
DK (1) DK3094353T3 (https=)
ES (1) ES2795727T3 (https=)
FI (1) FIC20230016I1 (https=)
FR (1) FR23C1016I1 (https=)
HR (1) HRP20200607T1 (https=)
HU (2) HUE048855T2 (https=)
LT (2) LT3094353T (https=)
LU (1) LUC00305I2 (https=)
MX (1) MX374517B (https=)
NL (1) NL301228I2 (https=)
NO (1) NO2023016I1 (https=)
PL (1) PL3094353T3 (https=)
PT (1) PT3094353T (https=)
RS (1) RS60387B1 (https=)
SI (1) SI3094353T1 (https=)
SM (1) SMT202000282T1 (https=)
TW (1) TWI705974B (https=)
WO (1) WO2015108967A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CA3229901A1 (en) 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
WO2013177264A1 (en) 2012-05-22 2013-11-28 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
US9273118B2 (en) * 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
WO2013177264A1 (en) 2012-05-22 2013-11-28 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma

Also Published As

Publication number Publication date
EP3094353A4 (en) 2017-09-06
NO2023016I1 (no) 2023-04-25
CY2023011I1 (el) 2023-11-15
JP2025063143A (ja) 2025-04-15
US11661449B2 (en) 2023-05-30
US12173050B2 (en) 2024-12-24
CN116355080A (zh) 2023-06-30
ES2795727T3 (es) 2020-11-24
MX374517B (es) 2025-03-06
US20220098285A1 (en) 2022-03-31
PT3094353T (pt) 2020-06-08
WO2015108967A3 (en) 2015-09-03
CA2933200A1 (en) 2015-07-23
US20250179153A1 (en) 2025-06-05
FR23C1016I1 (fr) 2023-06-23
AU2015206570A1 (en) 2016-07-14
HK1225992A1 (en) 2017-09-22
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
AU2021204339B2 (en) 2024-11-14
LUC00305I2 (https=) 2025-09-22
CY2023011I2 (el) 2023-11-15
EP3094353A2 (en) 2016-11-23
AU2020203831A1 (en) 2020-07-02
CA2933200C (en) 2025-05-06
EP3741390A1 (en) 2020-11-25
CY1123425T1 (el) 2021-12-31
FIC20230016I1 (fi) 2023-04-26
RS60387B1 (sr) 2020-07-31
US20190106482A1 (en) 2019-04-11
EP3094353B1 (en) 2020-04-01
BR112016015044A2 (pt) 2017-09-19
SMT202000282T1 (it) 2020-07-08
JP2017504321A (ja) 2017-02-09
JP2020103293A (ja) 2020-07-09
HRP20200607T1 (hr) 2020-07-10
ES2795727T9 (en) 2026-01-21
PL3094353T3 (pl) 2020-09-07
BR112016015044A8 (pt) 2023-04-11
HUE048855T2 (hu) 2020-08-28
AU2025201056A1 (en) 2025-03-06
JP2023052693A (ja) 2023-04-11
NL301228I1 (https=) 2023-05-03
LT3094353T (lt) 2020-08-10
HUS2300019I1 (hu) 2023-05-28
EP4353316A2 (en) 2024-04-17
WO2015108967A2 (en) 2015-07-23
AU2021204339A1 (en) 2021-07-22
WO2015108967A8 (en) 2015-10-01
MX2016008639A (es) 2017-02-15
TW201612191A (en) 2016-04-01
RU2016133247A3 (https=) 2019-01-16
SI3094353T1 (sl) 2020-07-31
DK3094353T3 (da) 2020-06-02
EP4353316A3 (en) 2024-08-21
JP6836398B2 (ja) 2021-03-03
LTC3094353I2 (https=) 2025-07-10
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CN105916520A (zh) 2016-08-31
RU2016133247A (ru) 2018-02-20
LTPA2023514I1 (https=) 2023-05-25
KR20160104018A (ko) 2016-09-02
US20230365660A1 (en) 2023-11-16
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
KR102188437B1 (ko) Rsv 특이적 항체 및 이의 기능적 부위
US20120114664A1 (en) Antibodies against h5n1 strains of influenza a virus
WO2018083538A1 (en) Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
JP2024522670A (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
JP6538151B2 (ja) 抗ｃ型肝炎抗体及びその抗原結合断片
RU2785598C2 (ru) Rsv-специфичные антитела и их функциональные части
HK40109087A (en) Rsv-specific antibodies and functional parts thereof
HK40041855A (en) Rsv-specific antibodies and functional parts thereof
HK1225992B (en) Rsv-specific antibodies and functional parts thereof
US20250382354A1 (en) Cross-specific antibodies, uses and methods for discovery thereof
US20250026815A1 (en) Anti-rsv antibody and application thereof
BR112016015044B1 (pt) Anticorpos específicos para rsv e partes funcionais dos mesmos

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1 3 5, Period Limitation Text : 1036, Comment Text :

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6

G20 Pte granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G20-TEX-PE0702 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1 3 5, Period Limitation Text : 1035, Comment Text :

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000